RT @Yuz6Yusof: #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significa
Tweet Content
#EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favoured DAZ Group. Phase 3 RCTs are underway @RheumNow https://t.co/I9uHxvRlnr
Show on Archive Page
On
Display in Search Results
On
PDQ
Off